- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 23, 2022
Highlights
- EPS (TTM)
- -$1.90
- Total Revenue (TTM)
- $22.57M
- Gross Profit (TTM)
- $19.47M
- EBITDA (TTM)
- -$173.45M
- Year Range
- $17.67 - $42.21
- Target Price
- $46.00
- ROA (TTM)
- -22.42%
- ROE (TTM)
- -24.70%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NAMS Performance Chart
NewAmsterdam Pharma Company N.V. (NAMS) is down 12.1% since the beginning of the year. At $31 per share, NAMS is trading 27.0% below its 52-week high of $42.
Loading charts...
Returns By Period
NewAmsterdam Pharma Company N.V. (NAMS) has returned -12.14% so far this year and 71.60% over the past 12 months.
NewAmsterdam Pharma Company N.V.
- 1D
- 3.32%
- 1M
- -13.04%
- YTD
- -12.14%
- 6M
- -15.54%
- 1Y
- 71.60%
- 3Y*
- 36.19%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NAMS Monthly Returns History
Based on dividend-adjusted daily data since Nov 23, 2022, NAMS's average daily return is +0.21%, while the average monthly return is +3.75%. At this rate, an investment would double in approximately 1.6 years.
Historically, 48% of months were positive and 52% were negative. The best month was Jan 2024 with a return of +83.3%, while the worst month was Nov 2022 at -26.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, NAMS closed higher 49% of trading days. The best single day was Dec 10, 2024 with a return of +41.4%, while the worst single day was Jan 31, 2023 at -24.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.29% | 13.95% | -9.73% | -10.78% | 17.93% | -8.49% | -12.14% | ||||||
| 2025 | -13.27% | -5.79% | -2.52% | -6.55% | -5.33% | -0.00% | 20.43% | 10.27% | 18.25% | 33.44% | 8.83% | -15.06% | 36.50% |
| 2024 | 83.26% | 11.58% | 3.55% | -7.78% | -14.03% | 2.45% | -10.88% | -4.09% | 1.10% | 2.53% | 16.63% | 29.47% | 130.08% |
| 2023 | 22.71% | -1.31% | 0.45% | 7.32% | -2.60% | -14.21% | -3.11% | -10.50% | -10.28% | -2.70% | 8.44% | 14.45% | 2.48% |
| 2022 | -26.36% | 34.57% | -0.91% |
Benchmark Metrics
NewAmsterdam Pharma Company N.V. has an annualized alpha of 45.14%, beta of 0.85, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 23, 2022.
- This stock captured 116.05% of S&P 500 Index gains but only 37.09% of its losses - a favorable profile for investors.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 45.14%
- Beta
- 0.85
- R²
- 0.03
- Upside Capture
- 116.05%
- Downside Capture
- 37.09%
Return for Risk
Risk / Return Rank
NAMS ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NewAmsterdam Pharma Company N.V. (NAMS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NAMS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.76 | ||
| Sortino ratioReturn per unit of downside risk | -0.77 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.37 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 2.29 | 2.78 | -0.49 |
| Martin ratioReturn relative to average drawdown | 4.53 | 12.44 | -7.90 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NewAmsterdam Pharma Company N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NewAmsterdam Pharma Company N.V. was 66.23%, occurring on Oct 25, 2023. Recovery took 58 trading sessions.
The current NewAmsterdam Pharma Company N.V. drawdown is 25.65%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -66.23%Oct 2023 | 8mo 27d | 2mo 26d | 11mo 23dJan 2023 - Jan 2024 |
2025 selloff2025 | -44.01%Apr 2025 | 3mo 23d | 4mo 28d | 8mo 21dDec 2024 - Sep 2025 |
2024 bear market2024 | -37.10%Sep 2024 | 7mo | 1mo 17d | 8mo 17dFeb 2024 - Nov 2024 |
2026 bear market2026 | -31.41%Apr 2026 | 5mo 2d | — | 6mo 27dNov 2025 - now |
2024 bear market2024 | -27.63%Dec 2024 | 20d | 5d | 25dNov 2024 - Dec 2024 |
Drawdown Indicators
| NAMS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -66.23% | -56.78% | -9.45% |
Max Drawdown (1Y)Largest decline over 1 year | -31.41% | -9.10% | -22.31% |
Max Drawdown (3Y)Largest decline over 3 years | -50.98% | -18.90% | -32.08% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -25.65% | -1.80% | -23.85% |
Average DrawdownAverage peak-to-trough decline | -22.13% | -10.71% | -11.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.84% | 2.03% | +13.81% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NewAmsterdam Pharma Company N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NewAmsterdam Pharma Company N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NAMS relative to other companies in the Biotechnology industry. Currently, NAMS has a P/S ratio of 118.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NAMS
Add NewAmsterdam Pharma Company N.V. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NAMS